Study results offer another boon for PARP inhibitors in treatment of advanced breast cancer

(University of Pennsylvania School of Medicine) Patients with certain advanced hereditary breast cancers may have new treatments options on the horizon, according to two studies presented this week at the annual San Antonio Breast Cancer Symposium. Susan Domchek, M.D., executive director of the Basser Center for BRCA at Penn's Abramson Cancer Center, will present new results from the Mediola and OlympiAD trials showing continued success of treating BRCA-related metastatic breast cancer with the PARP inhibitor olaparib with limited side effects for patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news